STC DRUG PRODUCT

AN INNOVATION TO MIMIC PATIENT'S RELAPSING CONDITIONS

EDUCATING IMMUNE SYSTEM TO ANTICIPATE RELAPSE MECHANISMS

aQualitative cancer-related proteins overexpressed.

By stimulation of selected tumor cell lines with standards of care used in the targeted indication.

RT: MUC1 (CRC)

Mucine; Cell Surface Associated – Overexpression associated with carcinomas

RT: MDR1 (CRC)

ATP efflux pump – Therapeutic resistance

TP: EPCAM

Marker for carcinoma – Fast growing epithelial tumors

RT: ABCC1

ABC transporter – Multiple Therapeutics resistance

TS: ICAM1 (CRC)

Widely expressed in tumor cells – Tumor progression

… 100+ Validated by multi-omics analysis.

ENSURING IMMUNE SYSTEM ACTIVATION

bHaptenization: boosting antigen's immune recognition.

Hapten

Immunogenic molecule

Carrier

Cancer-related Antigen

  • Immunogenic complex
  • Immunogenic system recognition
  • Cross-priming reaction (Memory process)
cAllogeneic tumor ghost cells
  • Dead cell but whole-membrane
  • Non proliferative
  • Critical size to boost APC recognition

FIRST-IN-CLASS TUMOR ANTIGEN-FOCUSED IMMUNOTHERAPY

Anticipating tumor plasticity from early stage to relapsing disease.

Meet our STC 1010

STC TECHNOLOGY EDUCATES IMMUNE SYSTEM TO RECOGNIZE AND ANTICIPATE ESCAPE MECHANISMS IN COLD TUMOR.

What happens in vivo after ID injection ?

STEP-2-1-5-e1672656844576
Step 1

APC* Cross priming activation

Petient's Dentritic Cells maturation with no HLA restriction.
(*Antigen-Presenting Cell ; Dentritic Cells)

Step-3-1-2
Step 2

TILs education

TILs (Tumor-Inflitrating Lymphocytes) pool generation multispecific of resistance factors: TAA/TSA.
(TAA = Tumor Associated Antigens & TSA = Tumor Specific Antigens)

step-4-2
Step 3

TILs expansion

The Multi specific TILs Pool generated expands, ready for TSA/TAA recognition.

Image1-4
Step 4

Patient's resistance tumor cells' destruction

TILs synergize on multiple qualitative targets and enhance immune modulators repsonse in combination.

A LIMITLESS POTENTIAL TO GENERATE FIRST-IN-CLASS IMMUNOTHERAPIES

Cell lines selection from tumor banks :

aIA/Data mining screening processed using specific criteria

bIn Vitro validation

PROVIDING A UNIQUE
VALUE PROPOSAL IN THE FIELD

Ready to use, standardized & scalable
  • Defined biological raw material (cell banks)
  • GLP/GMP Pharmaceutical development & Pre scale-up validated
FDA PRE IND & FAMHP (EMA) Scientific advises passed
Quick generation of First-In-Class Therapies

Patented platform, protected in key countries

Limitless potential to generate a strong pipeline

 

LEVERAGING OUR PLATFORM TO GENERATE STRONG CANDIDATES.

INTERESTED
IN OUR TECHNOLOGY ?

Meet our experts

STAY TUNED

NEWS

  • Press Release

Brenus annouces its international scientific committee.

Read more

NEWS

  • Scientific results

ASCO annual meeting 2023 (HCL, Inovotion, Explicyte, IRCM, CGFL)

Read more

NEWS

  • Scientific results

Poster AACR Annual meeting 2023 (Explicyte, Institut Bergonié)

Read more

NEWS

  • Scientific results

Poster AACR Annual meeting 2023 (Inovotion)

Read more

NEWS

  • Scientific results

Poster SITC Annual Meeting 2022 (CLB, IRCM)

Read more

NEWS

  • Scientific results

Poster SITC annual meeting 2022 (Inovotion)

Read more

INCREASE IMMUNOGENICITY

Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets

More about Haptenization & STC immunogenicity
Back to the page

REPRESENT HETEROGENEITY OF THE TARGETED INDICATION

Selection criteria of starting material (Allogeneic tumor cell lines)

  • Representative oncogenic drivers (TP53,BRAF,KRAS,…)
  • Cold & hot tumor cell lines
  • Resistances capacities (metabolic ; chemical & physical)
Back to the page

Increase antigenicity

Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with a broad & higher quality range of tumor antigens

More about STC Antigenicity
Back to the page